|
Evaluation of the MiCheck MIA test performance in differentiating aggressive from non-aggressive prostate cancer: The MiCheck-01 prospective trial. |
|
|
Leadership - Large Urology Group Practice Association |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Sanofi; Tolmar |
|
Christopher Michael Pieczonka |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Auxilium; Bayer; Dendreon; Janssen; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Auxilium; Bayer; Dendreon; Janssen; Sanofi |
Speakers' Bureau - Astellas Pharma; Auxilium; Bayer; Dendreon; Janssen; Sanofi |
Research Funding - Astellas Pharma (Inst); Bayer; Dendreon (Inst); Janssen (Inst); Medivation (Inst); Millennium |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Dendreon; Valeant/Dendreon |
|
Jennifer Lynn Beebe-Dimmer |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Minomic |
|
|
|
|
|
|
Patents, Royalties, Other Intellectual Property - Minomic (Inst) |
|
|
|
Stock and Other Ownership Interests - Minomic |
Patents, Royalties, Other Intellectual Property - Minomic (Inst) |
|
|
No Relationships to Disclose |